
1. J Antimicrob Chemother. 2013 Mar;68(3):690-6. doi: 10.1093/jac/dks455. Epub 2012 
Nov 14.

Role and evolution of viral tropism in patients with advanced HIV disease
receiving intensified initial regimen in the ANRS 130 APOLLO trial.

Charpentier C(1), Joly V, Larrouy L, Fagard C, Visseaux B, de Verdière NC, Raffi 
F, Yeni P, Descamps D; ANRS 130 APOLLO Trial Study Group.

Collaborators: Aumaître H, Medus M, Neuville S, Saada M, Abgrall S, Bentata M,
Bouchaud O, Cailhol J, Cordel H, Dhote R, Gros H, Honoré-Berlureau P, Huynh T,
Krivitzky A, Mansouri R, Poupard M, Prendki V, Radia D, Rouges F, Touam F, Warde 
B, de Castro N, Colin de Verdière N, Delgado J, Ferret S, Gallien S, Kandel T,
Lafaurie M, Lagrange M, Lascoux-Combe C, Le D, Molina JM, Pavie J, Pintado C,
Ponscarme D, Rachline A, Rozenbaum W, Sereni D, Taulera O, Estavoyer JM, Faucher 
JF, Foltzer A, Hoen B, Hustache-Mathieu L, Dupon M, Dutronc H, Neau D, Ragnaud
JM, Raymond I, Boucly S, Lortholary O, Viard JP, Bechara C, Delfraissy JF, Ghosn 
J, Goujard C, Kamouh W, Môle M, Quertainmont Y, Bergmann JF, Boulanger E,
Castillo H, Parrinello M, Rami A, Sellier P, Lepeu G, Pichancourt G, Bernard L,
Berthé H, Clarissou J, Gory M, Melchior JC, Perronne C, Stegman S, de Truchis P, 
Derradji O, Malet M, Teicher E, Vittecoq D, Chakvetadze C, Fontaine C, Lukiana T,
Pialloux G, Slama L, Bonnet D, Boucherit S, El Alami Talbi N, Fournier I, Gervais
A, Joly V, Iordache L, Laurichesse JJ, Leport C, Pahlavan G, Phung BC, Yeni P,
Bennamar N, Brunet A, Guillevin L, Salmon-Ceron D, Tahi T, Chesnel C, Dominguez
S, Jouve P, Lelièvre JD, Levy Y, Melica G, Sobel A, Ben Abdallah S, Bonmarchand
M, Bricaire F, Herson S, Iguertsira M, Katlama C, Kouadio H, Schneider L, Simon
A, Valantin MA, Abel S, Beaujolais V, Cabié A, Liauthaud B, Pierre François S,
Abgueguen P, Chennebault JM, Loison J, Pichard E, Rabier V, Delaune J, Louis I,
Morlat P, Pertusa MC, Brunel-Delmas F, Chiarello P, Jeanblanc F, Jourdain JJ,
Livrozet JM, Makhloufi D, Touraine JL, Augustin-Normand C, Bailly F, Benmakhlouf 
N, Brochier C, Cotte L, Gueripel V, Koffi K, Lack P, Lebouché B, Maynard M,
Miailhes P, Radenne S, Schlienger I, Thoirain V, Trepo C, Drogoul MP, Fabre G,
Faucher O, Frixon-Marin V, Gastaut JA, Peyrouse E, Poizot-Martin I, Jacquet JM,
Le Facher G, Merle de Boever C, Reynes J, Tramoni C, Allavena C, Billaud E, Biron
C, Bonnet B, Bouchez S, Boutoille D, Brunet-François C, Hüe H, Mounoury O, Raffi 
F, Reliquet V, Aubry O, Esnault JL, Leautez-Nainville S, Perré P, Suaud I, Bréaud
S, Ceppi C, Dellamonica P, De Salvador F, Durant J, Ferrando S, Fuzibet JG,
Leplatois A, Mondain V, Perbost I, Pugliese P, Rahelinirina V, Rosenthal E,
Sanderson F, Vassalo M, Arvieux C, Chapplain JM, Michelet C, Ratajczak M, Revest 
M, Souala F, Tattevin P, Chéneau C, Fischer P, Lang JM, Partisani M, Rey D,
Bastides F, Besnier JM, Le Bret P, Choutet P, Dailloux JF, Guadagnin P, Nau P,
Rivalain J, Soufflet A, Aïssi E, Melliez H, Pavel S, Mouton Y, Yazdanpanah Y,
Boyer L, Burty C, Letranchant L, May T, Wassoumbou S, Blum L, Danne O, Arthus MA,
Dion P, Certain A, Tabuteau S, Beuscart A, Agher N, Frosch A, Couffin-Cadiergues 
S, Diallo A.

Author information: 
(1)Laboratoire de Virologie, Assistance Publique-Hôpitaux de Paris (AP-HP),
Groupe Hospitalier Bichat-Claude Bernard, HUPNVS, Université Paris Diderot, Paris
7, PRES Sorbonne Paris Cité, EA4409, 75018, Paris, France.

OBJECTIVES: The aims of the study were to assess in patients with advanced HIV
disease receiving antiretroviral therapy (ART) intensification with enfuvirtide
(i) resistance at virological failure (VF), (ii) impact of baseline tropism on
immunovirological response, and (iii) HIV-1 DNA tropism evolution during ART.
METHODS: The ANRS 130 APOLLO randomized trial evaluated in naive patients the
immunovirological impact of standard ART without (control arm) or with
enfuvirtide. Tropism was determined on RNA and DNA by V3-loop sequencing
interpreted using the Geno2Pheno algorithm.
RESULTS: At baseline the median CD4 cell count was 30 cells/mm(3). Among the 170 
patients assessable in this virological substudy, HIV-1 RNA tropism was as
follows: 60% of viruses were R5 and 40% were R5X4/X4. HIV-1 DNA tropism was as
follows: 54% were R5 and 46% were R5X4/X4. At week 24, 39% and 49% of patients
experienced VF in the enfuvirtide and control arms, respectively. In the
enfuvirtide arm, only resistance-associated mutations to enfuvirtide were
detected. In the control arm, two patients displayed drug-resistant viruses at
the time of VF. No impact of baseline tropism was observed on immunovirological
response, regardless of the study arm. Among the 25 patients experiencing DNA
tropism switch between baseline and week 24, 16 (64%) switched from R5 to
R5X4/X4. These latter were mostly successfully suppressed patients receiving
enfuvirtide and exhibiting poorer immunological response.
CONCLUSIONS: Baseline RNA tropism had no impact on the immunovirological
response. Drug resistance mutations were only detected for the fusion inhibitor. 
Finally, the mechanism of replenishment of the viral cellular reservoir with X4
viruses observed needs to be further analysed.

DOI: 10.1093/jac/dks455 
PMID: 23152480  [Indexed for MEDLINE]

